Becotatug vedotin

Becotatug vedotin, also known by its development code MRG003, is a protein-based substance classified in the therapeutic area of neoplasms. It is an investigational medicine with no marketing authorisation in the product records, supplied by Lepu Biopharma Co., Ltd.^[1] The substance is given as a solution for infusion by intravenous injection.^[1]

Table of contents

• What is becotatug vedotin?
• How does becotatug vedotin work?
• Which conditions is becotatug vedotin studied for?
• How is becotatug vedotin given?
• What do the clinical trials show?
• What side effects are known?

What is becotatug vedotin?

Becotatug vedotin is an antibody-drug conjugate, a type of targeted cancer therapy that links an antibody to a cell-killing drug. The antibody part is designed to recognise and attach to a specific target on cancer cells, carrying the toxic payload directly to them. The substance is registered under the name MRG003 and is of protein origin.^[1] It is not yet authorised as a medicine; it remains an investigational substance studied in clinical trials.^[1]

How does becotatug vedotin work?

The trial record describes becotatug vedotin as an EGFR-ADC, meaning it targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many cancer cells, including those of head and neck squamous cell carcinoma. By binding to EGFR, the antibody-drug conjugate is taken up by the cancer cell, where the attached drug is released to kill it. The trial compares this mechanism alone with its combination with an anti-PD-1 immunotherapy, pucotenlimab, which helps the immune system attack cancer cells.^[1]

Which conditions is becotatug vedotin studied for?

• Locally advanced head and neck squamous cell carcinoma — a cancer of the mucosal surfaces of the head and neck that has grown locally but has not spread to distant organs. The registered trial studies becotatug vedotin as induction treatment before chemoradiotherapy in this condition.^[1]

A supplementary source also lists nasopharyngeal cancer as an indication for a separate Phase 3 trial of becotatug vedotin in combination with PD-1 blockade and chemoradiotherapy, though that trial is not part of the EU registry data provided here.^[2]

How is becotatug vedotin given?

Becotatug vedotin is formulated as a solution for infusion and is given by intravenous injection.^[1] In the registered Phase 2 trial, the dose used is 2.3 mg per kilogram of body weight.^[1] The medicine is administered in cycles, with the induction phase response assessed 21 days after the last cycle.^[1]

What do the clinical trials show?

The EU Clinical Trials Information System contains one authorised Phase 2 trial of becotatug vedotin, which is interventional and plans to enrol 106 participants.^[1] The trial compares induction treatment with becotatug vedotin alone against becotatug vedotin combined with pucotenlimab, an anti-PD-1 immunotherapy, both given before chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma.^[1]

The primary outcome is the best objective response rate, defined as the proportion of patients achieving a complete or partial response, evaluated by investigators using head and neck radiological imaging according to RECIST version 1.1 criteria at the end of the induction phase.^[1] The trial is currently authorised, meaning it has received regulatory approval to proceed in the EU.^[1]

Participants are adults with locally advanced head and neck squamous cell carcinoma who are candidates for induction treatment followed by chemoradiotherapy. The trial excludes patients whose cancer has spread to distant sites.^[1]

What side effects are known?

No side effect information is provided in the registry or supplementary sources for becotatug vedotin. As an investigational antibody-drug conjugate, its safety profile is still being established in clinical trials.^[1][2]